Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 18

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 18
---
 of the common warrants pursuant to the “alternative cashless exercise” provisions therein would be 450,000,000 (based on an assumed public offering price of $0.80 per share).

When the above provisions in the common warrants are utilized, our stockholders will most likely suffer substantial dilution.

We will likely not receive any additional funds upon the exercise of the common warrants.

The common warrants may be exercised by way of an alternative cashless exercise, in which case the holder would not pay a cash purchase price upon exercise, but instead would receive upon such exercise the number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the common warrant multiplied by (ii) 3.0. Accordingly, it is highly unlikely that a holder of the common warrants would wish to pay an exercise price in cash to receive one share of Common Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three shares of Common Stock. As a result, we will likely not receive, and do not expect to receive, any additional funds upon the exercise of the common warrants.

The exercisability of the common warrants is contingent upon us obtaining Stockholder Approval. If we do not obtain such Stockholder Approval, the common warrants may never become exercisable.

The common warrants are not immediately exercisable, as their exercisability is contingent upon us obtaining Stockholder Approval. The common warrants will become exercisable on Initial Exercise Date (i.e., the date on which Stockholder Approval is received) and will expire two and one-half (2.5) years after the Initial Exercise Date. We have agreed to hold a meeting to obtain Stockholder Approval as soon as practicable following the closing of this offering, but no later than sixty (60) days following the closing of this offering, and further agreed to cause an additional stockholder meeting to be held every ninety (90) days thereafter until such Stockholder Approval is obtained. We cannot assure you that we will be able to obtain requisite Stockholder Approval. In the event that we cannot obtain Stockholder Approval, the common warrants may never become exercisable. If we are unable to obtain Stockholder Approval, the common warrants will have no value.

Management will have broad discretion as to the use of the proceeds from the offering and uses may not improve our financial condition or market value.

Because we have not designated the amount of net proceeds from the offering to